Therapy of pulmonary hypertension in neonates and infants

Pharmacology and Therapeutics

Volumn 114, Issue 3, 2007, Pages 318-326

  Hoehn, Thomas ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Bosentan; Nitric oxide; Persistent pulmonary hypertension of the newborn; Prostacyclin; Pulmonary arterial hypertension; Sildenafil

Indexed keywords

4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; ADRENOMEDULLIN; AMBRISENTAN; BERAPROST; BOSENTAN; CYCLIC AMP; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; FLUOXETINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; NIFEDIPINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE III INHIBITOR; SILDENAFIL; SITAXSENTAN; UNIPROST; VASCULOTROPIN; VASOACTIVE INTESTINAL POLYPEPTIDE;

CELL PROLIFERATION; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; HUMAN; LUNG VASOCONSTRICTION; NONHUMAN; OXYGEN THERAPY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; HYPERTENSION, PULMONARY; INFANT; INFANT, NEWBORN; LUNG;

EID: 34249810023     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2007.03.006     Document Type: Review

References (86)

1. Abman S.H. Pulmonary hypertension in older children: new approaches and therapies. Paediatr Respir Rev 7 Suppl 1 (2006) S177-S179
2. Atz A.M., Adatia I., Lock J.E., and Wessel D.L. Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing. J Am Coll Cardiol 33 3 (1999) 813-819
3. Baquero H., Soliz A., Neira F., Venegas M.E., and Sola A. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics 117 4 (2006) 1077-1083
4. Barst R.J., Ivy D., Dingemanse J., Widlitz A., Schmitt K., Doran A., et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 73 4 (2003) 372-382
5. Bassler D., Choong K., McNamara P., and Kirpalani H. Neonatal persistent pulmonary hypertension treated with milrinone: four case reports. Biol. Neonate 89 1 (2006) 1-5
6. British Cardiac Society Guidelines and Medical Practice Committee, a. a. b. t. B. T. S. a. t. B. S. o. R. Recommendations on the management of pulmonary hypertension in clinical practice. Heart 86 Suppl 1 (2001) I1-I13
7. Campian M.E., Hardziyenka M., Michel M.C., and Tan H.L. How valid are animal models to evaluate treatments for pulmonary hypertension?. Naunyn-Schmiedeberg's Arch Pharmacol 373 6 (2006) 391-400
8. Chang A.C., Zucker H.A., Hickey P.R., and Wessel D.L. Pulmonary vascular resistance in infants after cardiac surgery: role of carbon dioxide and hydrogen ion. Crit Care Med 23 3 (1995) 568-574
9. Chen S.J., Chen Y.F., Meng Q.C., Durand J., Dicarlo V.S., and Oparil S. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 79 6 (1995) 2122-2131
10. Cohen H., Chahine C., Hui A., and Mukherji R. Bosentan therapy for pulmonary arterial hypertension. Am J Health-Syst Pharm 61 11 (2004) 1107-1119
11. Conroy S., McIntyre J., and Choonara I. Unlicensed and off label drug use in neonates. Arch Dis Child, Fetal Neonatal Ed 80 2 (1999) F142-F144 discussion F144-145
12. Dakshinamurti S. Pathophysiologic mechanisms of persistent pulmonary hypertension of the newborn. Pediatr Pulmonol 39 6 (2005) 492-503
13. Deruelle P., Grover T.R., Storme L., and Abman S.H. Effects of BAY 41-2272, a soluble guanylate cyclase activator, on pulmonary vascular reactivity in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 288 4 (2005) L727-L733
14. Deruelle P., Balasubramaniam V., Kunig A.M., Seedorf G.J., Markham N.E., and Abman S.H. BAY 41-2272, a direct activator of soluble guanylate cyclase, reduces right ventricular hypertrophy and prevents pulmonary vascular remodeling during chronic hypoxia in neonatal rats. Biol Neonate 90 2 (2006) 135-144
15. Endo A., Ayusawa M., Minato M., Takada M., Takahashi S., and Harada K. Endogenous nitric oxide and endothelin-1 in persistent pulmonary hypertension of the newborn. Eur J Pediatr 160 4 (2001) 217-222
16. Everard M.L. Aerosol delivery in infants and young children. J Aerosol Med 9 1 (1996) 71-77
17. Farber H.W., and Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 351 16 (2004) 1655-1665
18. Farrow K.N., Fliman P., and Steinhorn R.H. The diseases treated with ECMO: focus on PPHN. Semin Perinatol 29 1 (2005) 8-14
19. Finer N., and Barrington K. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev 18 4 (2006) CD000399
20. Fox W.W., Gewitz M.H., Dinwiddie R., Drummond W.H., and Peckham G.J. Pulmonary hypertension in the perinatal aspiration syndromes. Pediatrics 59 2 (1977) 205-211
21. Furchgott R.F., and Vanhoutte P.M. Endothelium-derived relaxing and contracting factors. FASEB J 3 9 (1989) 2007-2018
22. Galie N., Humbert M., Vachiery J.L., Vizza C.D., Kneussl M., Manes A., et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 39 9 (2002) 1496-1502
23. Galie N., Manes A., and Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 61 2 (2004) 227-237
24. Geggel R.L., Aronovitz M.J., and Reid L.M. Effects of chronic in utero hypoxemia on rat neonatal pulmonary arterial structure. J Pediatr 108 5 Pt 1 (1986) 756-759
25. Grover T.R., Parker T.A., Zenge J.P., Markham N.E., Kinsella J.P., and Abman S.H. Intrauterine hypertension decreases lung VEGF expression and VEGF inhibition causes pulmonary hypertension in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 284 3 (2003) L508-L517
26. Grover T.R., Parker T.A., and Abman S.H. Vascular endothelial growth factor improves pulmonary vascular reactivity and structure in an experimental model of chronic pulmonary hypertension in fetal sheep. Chest 128(6 Suppl) (2005) 614S
27. Guignabert C., Raffestin B., Benferhat R., Raoul W., Zadigue P., Rideau D., et al. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 111 21 (2005) 2812-2819
28. Haworth S.G. Development of the normal and hypertensive pulmonary vasculature. Exp Physiol 80 5 (1995) 843-853
29. Hill N.S., Warburton R.R., Pietras L., and Klinger J.R. Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats. J Appl Physiol 83 4 (1997) 1209-1215
30. Hironaka E., Hongo M., Sakai A., Mawatari E., Terasawa F., Okumura N., et al. Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Cardiovasc Res 60 3 (2003) 692-699
31. Hoehn T., and Krause M.F. Response to inhaled nitric oxide in premature and term neonates. Drugs 61 1 (2001) 27-39
32. Hoehn T., Preston A.A., McPhaden A.R., Stiller B., Vogel M., Buhrer C., et al. Endothelial nitric oxide synthase (NOS) is upregulated in rapid progressive pulmonary hypertension of the newborn. Intensive Care Med 29 10 (2003) 1757-1762
33. Hoehn T., Krause M.F., and Buhrer C. Meta-analysis of inhaled nitric oxide in premature infants: an update. Klin Padiatr 218 2 (2006) 57-61
34. Hoehn T., William M., McPhaden A.R., Stannigel H., Mayatepek E., and Wadsworth R.M. Endothelial, inducible and neuronal nitric oxide synthase in congenital pulmonary lymphangiectasis. Eur Respir J 27 6 (2006) 1311-1315
35. Howard L., and Morrell N. New therapeutic agents for pulmonary vascular disease. Paediatr Respir Rev 6 4 (2005) 285-291
36. Humpl T., Reyes J.T., Holtby H., Stephens D., and Adatia I. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation 111 24 (2005) 3274-3280
37. Ignarro L.J., Byrns R.E., Buga G.M., and Wood K.S. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ Res 61 6 (1987) 866-879
38. Jain L., and Dudell G.G. Respiratory transition in infants delivered by cesarean section. Semin Perinatol 30 5 (2006) 296-304
39. Jain L., and Eaton D.C. Physiology of fetal lung fluid clearance and the effect of labor. Semin Perinatol 30 1 (2006) 34-43
40. Jeffery T.K., and Wanstall J.C. Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension. Pharmacol Ther 92 1 (2001) 1-20
41. Kinsella J.P., Neish S.R., Shaffer E., and Abman S.H. Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 340 8823 (1992) 819-820
42. Ladha F., Bonnet S., Eaton F., Hashimoto K., Korbutt G., and Thebaud B. Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxia-induced lung injury. Am J Respir Crit Care Med 172 6 (2005) 750-756
43. Lakshminrusimha S., and Steinhorn R.H. Pulmonary vascular biology during neonatal transition. Clin Perinatol 26 3 (1999) 601-619
44. Lassus P., Turanlahti M., Heikkila P., Andersson L.C., Nupponen I., Sarnesto A., et al. Pulmonary vascular endothelial growth factor and Flt-1 in fetuses, in acute and chronic lung disease, and in persistent pulmonary hypertension of the newborn. Am J Respir Crit Care Med 164 (10 Pt 1) (2001) 1981-1987
45. Le Cras T.D., Kim D.H., Gebb S., Markham N.E., Shannon J.M., Tuder R.M., et al. Abnormal lung growth and the development of pulmonary hypertension in the Fawn-hooded rat. Am J Physiol 277 (4 Pt 1) (1999) L709-L718
46. Limsuwan A., Pienvichit P., and Khowsathit P. Beraprost therapy in children with pulmonary hypertension secondary to congenital heart disease. Pediatr Cardiol 26 6 (2005) 787-791
47. Liu Y., Christou H., Morita T., Laughner E., Semenza G.L., and Kourembanas S. Carbon monoxide and nitric oxide suppress the hypoxic induction of vascular endothelial growth factor gene via the 5' enhancer. J Biol Chem 273 24 (1998) 15257-15262
48. Lyrene R.K., Welch K.A., Godoy G., and Philips III J.B. Alkalosis attenuates hypoxic pulmonary vasoconstriction in neonatal lambs. Pediatr Res 19 12 (1985) 1268-1271
49. Macdonald P.D., and Yu V.Y. Simultaneous measurement of preductal and postductal oxygen saturation by pulse oximetry in hyaline membrane disease. Arch Dis Child 67(10 Spec No) (1992) 1166-1168
50. McColm J.R., Cunningham S., Wade J., Sedowofia K., Gellen B., Sharma T., et al. Hypoxic oxygen fluctuations produce less severe retinopathy than hyperoxic fluctuations in a rat model of retinopathy of prematurity. Pediatr Res 55 1 (2004) 107-113
51. McLaughlin V.V., Shillington A., and Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106 12 (2002) 1477-1482
52. McLaughlin V.V., Gaine S.P., Barst R.J., Oudiz R.J., Bourge R.C., Frost A., et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 41 2 (2003) 293-299
53. Mikhail G., Gibbs J., Richardson M., Wright G., Khaghani A., Banner N., et al. An evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertension. Eur Heart J 18 9 (1997) 1499-1504
54. Murakami S., Kimura H., Kangawa K., and Nagaya N. Physiological significance and therapeutic potential of adrenomedullin in pulmonary hypertension. Cardiovasc Hematol Disord Drug Targets 6 2 (2006) 125-132
55. Murphy J.D., Rabinovitch M., Goldstein J.D., and Reid L.M. The structural basis of persistent pulmonary hypertension of the newborn infant. J Pediatr 98 6 (1981) 962-967
56. Nadeau S., Baribeau J., Janvier A., and Perreault T. Changes in expression of vascular endothelial growth factor and its receptors in neonatal hypoxia-induced pulmonary hypertension. Pediatr Res 58 2 (2005) 199-205
57. Oldfield V., and Lyseng-Williamson K.A. Bosentan: a review of its use in pulmonary arterial hypertension and systemic sclerosis. Am J Cardiovasc Drugs 6 3 (2006) 189-208
58. Perreault T. Persistent pulmonary hypertension of the newborn. Paediatr Respir Rev 7 Suppl 1 (2006) S175-S176
59. Petkov V., Mosgoeller W., Ziesche R., Raderer M., Stiebellehner L., Vonbank K., et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 111 9 (2003) 1339-1346
60. Phillips P.G., Long L., Wilkins M.R., and Morrell N.W. cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol 288 1 (2005) L103-L115
61. Proceedings of the 3rd World Symposium on Pulmonary Arterial Hypertension Venice, Italy, June 23-25, 2003. J Am Coll Cardiol 43 12 Suppl S (2004) 1S-90S
62. Rabinovitch M., Gamble W.J., Miettinen O.S., and Reid L. Age and sex influence on pulmonary hypertension of chronic hypoxia and on recovery. Am J Physiol 240 1 (1981) H62-H72
63. Rakotoniaina Z., Guerard P., Lirussi F., Goirand F., Rochette L., Dumas M., et al. The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin. Naunyn-Schmiedeberg's Arch Pharmacol 374 3 (2006) 195-206
64. Roberts J.D., Polaner D.M., Lang P., and Zapol W.M. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 340 8823 (1992) 818-819
65. Rosenzweig E.B., and Barst R.J. Idiopathic pulmonary arterial hypertension in children. Curr Opin Pediatr 17 3 (2005) 372-380
66. Rosenzweig E.B., Ivy D.D., Widlitz A., Doran A., Claussen L.R., Yung D., et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 46 4 (2005) 697-704
67. Runo J.R., and Loyd J.E. Primary pulmonary hypertension. Lancet 361 9368 (2003) 1533-1544
68. Ryhammer P.K., Shekerdemian L.S., Penny D.J., and Ravn H.B. Effect of intravenous sildenafil on pulmonary hemodynamics and gas exchange in the presence and absence of acute lung injury in piglets. Pediatr Res 59 6 (2006) 762-766
69. Schermuly R.T., Kreisselmeier K.P., Ghofrani H.A., Yilmaz H., Butrous G., Ermert L., et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 169 1 (2004) 39-45
70. Schermuly R.T., Yilmaz H., Ghofrani H.A., Woyda K., Pullamsetti S., Schulz A., et al. Inhaled iloprost reverses vascular remodeling in chronic experimental pulmonary hypertension. Am J Respir Crit Care Med 172 3 (2005) 358-363
71. Schermuly R.T., Schulz A., Ghofrani H.A., Breitenbach C.S., Weissmann N., Hildebrand M., et al. Comparison of pharmacokinetics and vasodilatory effect of nebulized and infused iloprost in experimental pulmonary hypertension: rapid tolerance development. J Aerosol Med 19 3 (2006) 353-363
72. Scheurer M., Bandisode V., and Atz A.M. Simplified pulmonary vasodilatory testing in the cardiac catheterization laboratory with nasal cannula nitric oxide. Pediatr Cardiol 27 1 (2006) 84-86
73. Schulze-Neick I., Hartenstein P., Li J., Stiller B., Nagdyman N., Hubler M., et al. Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. Circulation 108 Suppl 1 (2003) II167-II173
74. Sebkhi A., Strange J.W., Phillips S.C., Wharton J., and Wilkins M.R. Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation 107 25 (2003) 3230-3235
75. Shahbazian, A., Petkov, V., Baykuscheva-Gentscheva, T., Hoeger, H., Painsipp, E., Holzer, P., et al. (2006). Involvement of endothelial NO in the dilator effect of VIP on rat isolated pulmonary artery. Regul Pept., [Epub ahead of print].
76. Simonneau G., Galie N., Rubin L.J., Langleben D., Seeger W., Domenighetti G., et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43 12 Suppl S (2004) 5S-12S
77. Stenmark K.R., Fasules J., Hyde D.M., Voelkel N.F., Henson J., Tucker A., et al. Severe pulmonary hypertension and arterial adventitial changes in newborn calves at 4300 m. J Appl Physiol 62 2 (1987) 821-830
78. Tibballs J., and Chow C.W. Incidence of alveolar capillary dysplasia in severe idiopathic persistent pulmonary hypertension of the newborn. J Paediatr Child Health 38 4 (2002) 397-400
79. Travadi J.N., and Patole S.K. Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: a review. Pediatr Pulmonol 36 6 (2003) 529-535
80. Tulloh R. Management and therapeutic options in pediatric pulmonary hypertension. Expert Rev Cardiovasc Ther 4 3 (2006) 361-374
81. Tyler R.C., Muramatsu M., Abman S.H., Stelzner T.J., Rodman D.M., Bloch K.D., et al. Variable expression of endothelial NO synthase in three forms of rat pulmonary hypertension. Am J Physiol 276 2 Pt 1 (1999) L297-L303
82. Vitali S.H., and Arnold J.H. Bench-to-bedside review: Ventilator strategies to reduce lung injury-lessons from pediatric and neonatal intensive care. Crit Care 9 2 (2005) 177-183
83. Walsh-Sukys M.C., Tyson J.E., Wright L.L., Bauer C.R., Korones S.B., Stevenson D.K., et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 105 (2000) 14-20
84. Yoder B.A., Kirsch E.A., Barth W.H., and Gordon M.C. Changing obstetric practices associated with decreasing incidence of meconium aspiration syndrome. Obstet Gynecol 99 (2002) 731-739
85. Zhao Y.D., Courtman D.W., Deng Y., Kugathasan L., Zhang Q., and Stewart D.J. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res 96 4 (2005) 442-450
86. Ziegler J.W., Ivy D.D., Kinsella J.P., and Abman S.H. The role of nitric oxide, endothelin, and prostaglandins in the transition of the pulmonary circulation. Clin Perinatol 22 2 (1995) 387-403